In a review on “understanding and managing toxicities of VEGF inhibitors” Schmidinger forwarded the view that hypothyroidism induced by VSP-TKIs can contribute to their cardiotoxicity potential.64 Up to 85 and 21% of patients on sunitinib and sorafenib, respectively, develop subclinical or clinically overt hypothyroidism.65 Of note, both of these drugs have been used in the treatment of thyroid carcinoma owing to their potency to inhibit kinases involved in the growth and function of thyroid cells. This evidence concerns the gene VEGFA and hypothyroidism.